GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer

SYDNEY & LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #breastcancerawareness--GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDxTM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes. DCISionRT® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with b

Click to view original post